By Clarisse Douaud

9/13/2006 - New manufacturer and marketer Calgenex Corporation is
taking the condition-specific approach to supplementation to a very
specific level - tackling soft tissue calcification with a range of
products.

In an effort to set themselves apart from the crowd, more and more
manufacturers and distributors are marketing products to particular
health conditions, as such bypassing the dilemma of relying on
consumer nutritional education and instead directly labeling the
health condition a specific set of compounds supports.

Like many other supplement companies, Calgenex is aiming its soft
tissue calcification support products primarily at the baby boomer
generation - the generation with the most disposable income and also
the age bracket in which the condition manifests itself most
pervasively.

"The company was founded on the premise that calcification is a very
important condition facing Americans today," Calgenex president and
CEO Grant Carlson told NutraIngredients-USA.com. "We have too much
calcium in our bodies that is then forming calcium crystals in our
soft tissues."

The budding Tampa, Florida-based company was founded in February 2006
and has just announced the launch of its Calci Clear product line.
Carlson says the products will initially be marketed in the US through
both the Internet and infomercials, but he is relying on the
originality of the product health target to bring it to retail shelves
domestically and abroad.

"It's really a new category," said Carlson of the company's strategic
focus on supplementation for soft tissue calcification.

Calci Clear consists of a three-step program of supplements, which
Calgenex claims cleanses the body of calcium crystals while also
keeping new crystals from forming. The company website describes
ingredients EDTA (ethylenediaminetetraacetic acid), citric acid,
sodium citrate, malic acid, and green algae-derived chlorophyll as
"sequestering agents" that bind with unwanted calcium crystals and
heavy metals and flush them out of the body.

Carlson says Calgenex's blend of minerals, vitamins and chemical
compounds is patent-pending and tests are currently underway on its
products in various locations in the US. The Calci Clear ingredients
include: green algae chlorophyll, chlorella, as well as antioxidants
like alpha lipoic acid, pycnogenol pine bark extract, grape seed
extract and coenzyme Q10.

Under normal mineral conditions in the body, calcification is limited
to bones and teeth, but when soft tissue calcification occurs, tissue
hardens into bone-like material. While calcium is an essential
nutrient for the body, when other mineral deficiencies occur in the
body - according to Calgenex - an imbalance can result in calcium
flowing into the cells, which become more hyperactive and excitable.

Soft tissue calcification is associated with numerous chronic health
conditions such as atherosclerosis, arthritis, kidney stones,
prostatitis, psoriasis and cataracts. Also known as ectopic
calification, the condition can be associated with cell death and can
damage vessels, tissues, and internal organs.

Calgenex sought out its niche in a condition it says plays a role in
many serious diseases.

"We recognized that soft tissue calcification and inflammation were at
the heart of many health conditions affecting millions of Americans
and that they could be addressed by certain ingredients found in
nature," said Carlson.

A look at arthritis statistics gives a glimpse at the possible
occurrence of soft tissue calcification in the US. Soft tissue
calcification can result from arthritis - more specifically from
crystal deposition diseases that fall under the category of
inflammatory arthritis. And by 2030, an estimated 67 million of
Americans aged 18 years or older will have doctor-diagnosed arthritis,
according to data from the National Center for Health Statistics.

http://www.nutraingredients-usa.com/news/ng.asp?id=70518-calgenex-cal...

Wednesday October 3, 9:15 am ET

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP
- News; "Nanobac" or "the Company") announced today that it signed an
agreement with Calgenex granting Nanobac an option to assess Calgenex'
drug delivery technology for potential use with Nanobac's drug
combinations used in treating atherosclerosis, prostatitis, and other
pathologic calcification diseases. The technology includes a novel
combination of bisphosphonate and silicic acid.

"Today's option agreement is a testament towards our goal of
evaluating the best therapeutic delivery technologies used with our
compounds to treat diseases associated with pathologic calcification,"
commented Alex H. Edwards III Director, Nanobac Pharmaceuticals. "We
will be evaluating the Calgenex technology in the context of our drug
development efforts in order to improve on an important class of
drugs, namely bisphosphonates."

There are a number of bisphosphonate drugs on the market including
Fosamax, Evista, Actonel, and most recently Boniva. The administration
of these drugs has been historically problematic. Advances in delivery
mechanisms, such as enteric coatings and extended release formulas
have helped with patient compliance, however challenges still exist.
Nanobac is investigating the use of Bisphosphonates in combination
with other approved compounds for the treatment diseases associated
with soft tissue calcification, including atherosclerosis and
prostatitis.

Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For
more information, visit our website at: http://www.nanobac.com .

Contact:

Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348

Source: Nanobac Pharmaceuticals Inc.

2006-09-14 - Calgenex Corporation

TAMPA, Fla.--(BUSINESS WIRE)--Sept. 14, 2006--Calgenex Corporation
today announced that Joseph Jacobs, M.D., MBA, has joined the
nutraceutical and personal care products company in the position of
Consulting Medical Director.

Dr. Jacobs straddles the bridge between conventional and alternative
therapies. He received his medical degree from Yale University,
completed his residency at Dartmouth-Hitchcock Medical Center and Yale-
New Haven Medical Center, and obtained his masters in business
administration from the Wharton School of Business. He has authored
and/or contributed to eight books including Cancer: Principles and
Practice of Oncology, Medical Futility and the Complementary/
Alternative Medicine: An Evidenced-Based Approach. Yet this doctor is
just as familiar with traditional approaches to health care. Dr.
Jacobs' mother was a full-blooded Caughnawaga Mohawk Indian and his
father was part Cherokee. Growing up, he was exposed to numerous
herbal medicines and healing ceremonies to cure sickness.

His intimate knowledge of both traditional and conventional medicine
made Dr. Jacobs the perfect candidate for the position of director of
the Office of Alternative Medicine at the National Institutes of
Health, where he examined the scientific validity of various
alternative treatments, such as acupuncture, chiropractic, herbal
medicine, biofeedback and homeopathy.

"We are very pleased to have someone with Dr. Jacobs' experience in
both alternative medicine and health care administration on our
management team," commented Grant Carlson, president and CEO of
Calgenex. The company manufactures and markets dietary supplement,
topical over-the-counter (OTC) drugs, and personal care products
specially formulated to combat the effects of soft tissue
calcification and inflammation. "Dr. Jacobs began assisting the
Company shortly after its founding in February 2006. Dr. Jacobs has
always been a leader in healthcare innovation. As consulting medical
director, he will help guide the clinical development of our products
and communicate our message to both the medical community and the
general public."

Dr. Jacobs shared Carlson's enthusiasm. "There is strong evidence that
soft tissue calcification, or plaque, is a widespread health
phenomenon affecting the health and quality of life of millions of
Americans," stated Dr. Jacobs. "I think the folks at Calgenex are onto
something very exciting that may improve the lives of millions."

Founded in 2006, Calgenex Corporation manufactures and markets dietary
supplements, topical OTC drugs and personal care products specially
formulated to combat the effects of soft tissue calcification and
inflammation. Calgenex is located at 9950 Princess Palm Ave., Suite
320 in Tampa, Florida. For more information about the company or its
products, please visit http://www.calgenex.com , phone 813-623-5268,
or email gcarl...@calgenex.com .

http://www.npicenter.com/anm/templates/newsATemp.aspx?articleid=16545...

TAMPA, Fla. (BusinessWire EON) April 11, 2007 -- Calgenex Corporation
announced today the introduction of Calci-CLEAR, an exclusive line of
dietary supplements addressing calcification of the soft tissues
including the hardening of the arteries and inflammation. Calgenex is
one of the few companies in the world addressing this pervasive yet
often ignored health condition.

We recognize that calcification and inflammation are at the heart of
many of the health conditions affecting Americans today

Soft tissue calcification is the abnormal hardening or thickening of
tissue into bone like material sometimes referred to as hard plaque,
stones, or calcified deposits. Calcification is not classified as a
disease; however calcium deposits are often associated with many
chronic diseases including cancer, arthritis, diabetes, kidney stones,
psoriasis, and heart disease. Calcium buildup in arteries is an early
warning sign of increased risk of coronary heart disease. People with
higher arterial calcium levels are more likely to develop
atherosclerosis, stroke and other heart ailments later in life than
those with normal levels. In fact, some researchers and physicians now
argue that degree of calcification is a more important risk factor for
heart disease than cholesterol.

Historically, calcium deposits were thought to occur later in various
health conditions, although no exact mechanism has been discovered.
Recent studies illustrate, however, that calcium deposits may play a
much more active role. In fact, new research is showing that nano-
sized calcium phosphate crystals in the soft tissues can harm cells
and provoke inflammation.

“We recognize that calcification and inflammation are at the heart of
many of the health conditions affecting Americans today,” stated Grant
Carlson, president and CEO of Calgenex. “It is a little known fact
that calcification is associated with more than half of diseases on
the leading cause of death list. We developed Calci-CLEAR to help rid
the body of calcium phosphate crystals that may result in soft tissue
calcification and to potentially improve the quality of life for
countless individuals.”

Calci-CLEAR is a Three Step System that works in five ways:

    * Cleanses calcium crystals from the body through the use of
sequestering agents that help bind calcium crystals;
    * Activates proteins that inhibit soft tissue calcification, such
as the matrix GLA protein, through the use of ingredients such as
Vitamin K2;
    * Promotes mineral balance by rebalancing the body's mineral
stores to the ratios that nature intended;
    * Neutralizes harmful free radicals through powerful antioxidants;
and
    * Protects cardiovascular health through many heart healthy
ingredients such as Pycnogenol™, Schizandra, Astragalus, Pomegranate,
Grape seed extract, Resveratrol and Coenzyme Q10.(1)

The Calci-CLEAR system will soon be available through physician
offices and is currently available online at www.calgenex.com or
www.calciclear.com.

Calgenex Corporation manufactures and markets condition specific
dietary supplements, topical OTC drugs and personal care products.
Calgenex is located at 9950 Princess Palm Ave., Suite 320 in Tampa,
Florida.

For more information about the company or its products, please visit
www.calgenex.com, phone 813-623-5268, or email gcarl...@calgenex.com .

(1) These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure,
or prevent any disease.

http://eon.businesswire.com/releases/calgenex/calcification/prweb5182...